Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
923actual
Sites
260
Countries
Argentina, Brazil, Canada +27
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-06-25 | actual | When the study began enrolling |
| Primary completion | 2026-03-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-16 | estimated | The whole study's end, after follow-up |
| First posted | 2019-06-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Triple Negative Breast Neoplasms
Interventions
- Drug: Capivasertib — also filed as AZD5363
- Drug: Paclitaxel
- Drug: Placebo — also filed as Placebo tablets to match capivasertib
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured The time from date of randomisation to the date of death due to any cause up to approximately 42 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed